


Technology: Etanercept is a recombinant tumor necrosis factor receptor ("TNFR"):F_c fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.



Etanercept Timeline Nov. 1998 Aug. 2016 Apr. 2019 Enbrel® Biosimilar Erelzi® Biosimilar Eticovo™ **FDA** Approval FDA Approval FDA Approval (BL 103795) (aBL 761042) (aBL 761066) (Immunex (Amgen)) (Sandoz) (Samsung Bioepis) Aug. 2019 Dec. 2014 Feb. 2016 Jun. 2013 Sep. 2017 Amgen v. Sandoz Sandoz v. Sandoz v. Amgen Amgen v. IPR2017-02066 (2:16-cv-01118) (Fed. Cir. 14-1693, Sandoz Amgen Petition Filed Decision [Patents Not [Institution (3:13-cv-02904) Appeal of 3:13-cv-02904) (2:16-cv-01118) Invalid: Stipulated Complaint Filed Decision [Affirmed] **Complaint Filed** Denied] Infringement] Nov. 2013 Apr. 2019 Jul. 2020 Aug. 2015 Aug. 2017 Amgen v. Samsung Amgen v. Sandoz Sandoz v. Amgen IPR2015-01792 IPR2017-01916 (Fed. Cir. 20-1037) (3:13-cv-02904) Bioepis **Petition Filed** Petition Filed Motion to Dismiss Granted (2:19-cv-11755) Appeal of 2:16-cv-[Institution [Institution Complaint Filed 01118) Decision Denied] Denied] VENABLE | Fitzpatrick [Ongoing] [Affirmed]

	Sandoz v. Amgen 3:13-cv-02904 (N.D. Cal.) Dismissed for lack of subject matter jurisdiction; Fed. Cir. 14-1693 Affirmed	Amgen v. Sandoz 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulation of infringement; Appeal 20-1037 Affirmed, Request for <i>en banc</i> rehearing denied	<i>Amgen v. Samsung Bioepis</i> 2:19-cv- 11755 (D.N.J.) Ongoing	Coalition for Affordable Drugs v. Amgen IPR2015-01792 Institution denied	Coherus v. Hoffman-La Roche IPR2017-01916 Institution denied	Coherus v. Hoffman-La Roche IPR2017-02066 Institution denied
7,915,225		x	X			
8,063,182	x	x	x			X
8,119,605		x	x			
8,163,522	x	x	x	x	x	
8,722,631		x	x			